Adi Shaked
Associate
Get their honest, personalized take on your startup.
Sign in to pitch Adi →At a glance
- Full Name
- Adi Shaked
- Title
- Associate
- Firm
- SCP Vitalife Partners (the life-sciences fund affiliated with SCP Partners)
- Firm Type
- Venture capital (life sciences) — the stub's "Angel Investors" label appears inaccurate
- Investment Stage
- Early to mid-stage (Series A/B and growth); firm invests from company formation onward
- Check Size
- ~$3M–$7M per investment (firm level)
- Target Company Profile
- Life-science start-ups with breakthrough products addressing significant medical needs, concentrated in therapeutic medical devices
- Sector Focus
- Life sciences — therapeutic devices, healthcare technology systems, diagnostics
- Geographic Focus
- United States and Israel
- Location
- Wayne / Malvern, Pennsylvania (SCP Partners' U.S. office)
Background
Adi Shaked is an Associate at SCP Vitalife Partners, the life-sciences venture arm affiliated with SCP Partners in suburban Philadelphia. She joined SCP Vitalife in 2008, coming from Medtronic, where she was a Marketing Manager in the company's CardioVascular division. Earlier in her career she worked as a senior consultant at Navigant Consulting.
She holds an MBA from the Darden School of Business at the University of Virginia and a B.A. in Economics from Boston University, where she graduated Summa Cum Laude. Her combination of medical-device operating experience (Medtronic), management consulting (Navigant), and a top-tier MBA is typical of the operator-analyst profile SCP Vitalife brought onto its investment team.
SCP Vitalife Partners was founded in 2002 as a cross-border venture firm focused on life-science investments in Israel and the U.S., managing roughly $230 million across two funds and backing more than 30 life-science start-ups. It operates alongside the broader SCP Partners platform (a multi-stage VC firm founded in 1996, based in Malvern, PA, with historical focus areas spanning ICT, life sciences, services, and defense/security). Note that both SCP Partners and SCP Vitalife maintain older web presences, so this profile reflects a firm whose most active investing period was in the late 2000s and 2010s.
Investment Thesis & Focus
- Invests in early- to mid-stage life-science technologies and services, with a stated concentration on therapeutic medical devices
- Backs companies offering "breakthrough products addressing significant medical needs" (firm's own framing)
- Typical checks in the $3M–$7M range, drawn from a ~$230M two-fund life-sciences platform
- Cross-border strategy: pairs Israeli medical-device innovation with U.S. market access and capital (offices in the Tel Aviv/Ra'anana area and Wayne/Malvern, PA)
- As an Associate, Shaked's role centers on diligence, market analysis, and portfolio support rather than leading/pricing rounds — her Medtronic cardiovascular and consulting background maps to device-market and commercialization evaluation
Notable Investments
- Avedro — ophthalmic (corneal cross-linking) company; acquired by Glaukos Corporation, closing November 2019
- Regentis Biomaterials — regenerative orthopedic/cartilage-repair company; recorded as an SCP Vitalife exit in May 2023
- Ivenix — infusion-therapy / large-volume infusion pump maker (healthcare technology systems)
- Medical Surgery Technologies (M.S.T.) — surgical robotics / image-guided surgery
- Firm track record overall cited as 2 IPOs and ~6 acquisitions across its life-science portfolio
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.